Physician profile
Robert L Tobin
NPI 1912967050
$1,511.16
in general payments reported to CMS, 2019-2025
35 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $267 · 2021: $21.33 · 2022: $14.62 · 2023: $236 · 2024: $208 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $171.22 | 2023 | |
| Novartis Pharmaceuticals Corporation | $147.13 | 2019-2025 | |
| Amgen INC. | $115.66 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $98.36 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $84.95 | 2019-2020 | |
| Janssen Biotech, INC. | $72.28 | 2019-2025 | Rybrevant |
| Abbvie INC. | $66.98 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $60.56 | 2019-2024 | Imfinzi |
| Genentech USA, INC. | $58.17 | 2019-2025 | Venclexta |
| Incyte Corporation | $56.06 | 2019-2025 | Monjuvi, Pemazyre |
| Kyowa Kirin, INC. | $46.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.72 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $38.04 | 2025 | Orgovyx |
| Eisai INC. | $36.54 | 2020-2024 | |
| Genzyme Corporation | $32.71 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31.88 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $29.29 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Taiho Oncology, INC. | $28.00 | 2023-2024 | |
| Lilly USA, LLC | $27.65 | 2019 | |
| Glaxosmithkline, LLC. | $24.95 | 2020 | |
| Servier Pharmaceuticals LLC | $22.62 | 2024 | |
| Celgene Corporation | $21.49 | 2019 | |
| Heron Therapeutics, INC. | $20.58 | 2019 | |
| Adc Therapeutics America, INC. | $18.29 | 2024 | |
| Stemline Therapeutics INC. | $18.17 | 2024 | Orserdu |
| Daiichi Sankyo INC. | $15.65 | 2023 | Enhertu |
| Accord Healthcare, INC. | $15.62 | 2025 | |
| Beone Medicines USA, INC. | $15.00 | 2025 | Tevimbra |
| Octapharma USA, INC. | $14.90 | 2019 | |
| Aveo Pharmaceuticals, INC. | $14.62 | 2022 | |
| Boston Scientific Corporation | $14.16 | 2019 | |
| Rigel Pharmaceuticals, INC. | $13.39 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.23 | 2019 | |
| Coherus Oncology, INC. | $12.98 | 2023 | |
| Emd Serono, INC. | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.